UCB (UCB) Stock Price, Fundamentals & Analysis

What UCB does

UCB (UCB) is a biopharmaceutical stock listed on the Euronext Brussels market in the Healthcare sector, specifically the Biotechnology industry. The company develops products for people with neurology and immunology diseases worldwide. Its portfolio includes treatments such as Cimzia for various forms of arthritis and inflammatory bowel disease, Vimpat and Keppra for epilepsy, Neupro for Parkinson's disease, and Zyrtec for allergies. UCB also offers Bimzelx for plaque psoriasis and hidradenitis suppurativa, and RYSTIGGO for generalized myasthenia gravis. The company is part of the BEL 20 index and operates alongside peers like Novo Nordisk (NOVO-B) and AstraZeneca (AZN).

Key numbers explained

• The current share price is 214.4 EUR, reflecting the cost to buy one share today.
• The marketCap of 40.88B EUR represents the total market value of all outstanding shares.
• The trailing P/E ratio of 18.9 indicates how much investors pay per euro of the company's last 12 months of earnings.
• The forward P/E ratio of 15.6 uses expected future earnings, often providing a more current valuation perspective.
• The dividend yield of 0.68% shows the annual dividend payment as a percentage of the share price.
• The exDividendDate of May 4, 2026, is the date by which you must own the stock to receive the next dividend payment.
• The beta of 0.18 suggests the stock's price tends to be less volatile than the overall market.
• The priceToBook ratio of 3.51 compares the market price to the company's book value per share.

What to watch

Investors tracking UCB should monitor its revenue growth, which stands at 22.5% year over year, and its profit margin of 25.7%. The company's next earnings report is scheduled for Jul 30, 2026, which often drives price movement. The 52-week price range of 200.7 – 289.5 provides context for recent volatility. As a healthcare stock, regulatory approvals and clinical trial results for its drug pipeline are key factors. Comparing UCB to peers like arGEN-X (ARGX) or Fosun Pharmaceutical (600196) can offer broader sector perspective.